In this study, we identified PD-L1 expression with 1000 patient samples including 785 adenocarcinomas, 188 squamous cell carcinomas, 21 large cell neuroendocrine carcinomas, 4 carcinoid tumor, and 2 small cell carcinomas using the 22C3 PD-L1 assay. This evidence concerns the gene CD274 and large cell neuroendocrine carcinoma.